Thermo Fisher Scientific Inc. diskutieren

Thermo Fisher Scientific Inc. (NYSE: TMO) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. They now have a $630.00 price target on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at Morgan Stanley from $670.00 to $647.00. They now have an "overweight" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target raised by analysts at Morgan Stanley from $647.00 to $678.00. They now have an "overweight" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target raised by analysts at Wells Fargo & Company from $660.00 to $680.00. They now have an "overweight" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target raised by analysts at UBS Group AG from $700.00 to $715.00. They now have a "buy" rating on the stock.

Thermo Fisher looks like a solid buy right now. They knocked it out of the park with their Q4 results, beating revenue expectations and showing strong 5% organic growth. The company's innovation engine is firing on all cylinders, launching cool new products like the Stellar mass spectrometer. Their Accelerator Drug Development program also has me excited - it could be a game-changer for speeding up drug development. While there are some economic uncertainties, Thermo Fisher's diverse business and focus on cost management should help them weather any storms. With 6-8% EPS growth expected in 2025 and margin expansion to boot, I think this stock has room to run. The $650 target price reflects potential upside as the company executes on its growth strategy. Of course, keep an eye on those macro headwinds, but overall Thermo Fisher looks well-positioned to outperform.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $667.00 price target on the stock, up previously from $650.00.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at Wells Fargo & Company from $680.00 to $580.00. They now have an "overweight" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at Robert W. Baird from $603.00 to $573.00. They now have an "outperform" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at Wells Fargo & Company from $580.00 to $570.00. They now have an "overweight" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at Evercore ISI from $585.00 to $500.00. They now have an "outperform" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at Stifel Nicolaus from $665.00 to $620.00. They now have a "buy" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at UBS Group AG from $715.00 to $500.00. They now have a "buy" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at Royal Bank of Canada from $651.00 to $637.00. They now have an "outperform" rating on the stock.

Thermo Fisher Scientific Inc. (NYSE: TMO) had its price target lowered by analysts at Argus from $620.00 to $470.00. They now have a "buy" rating on the stock.